Stockhead’s Sarah Hughan sits down with Island Pharmaceuticals’ (ASX:ILA) managing director David Foster to get the short end of the long story on the company’s latest news.

The company’s ISLA-101 lead molecule has been shown to provide anti dengue fever virus activity in a clinical trial.

In the trial, subjects received a weakened dengue virus developed by the US army after receiving the drug.

Tune in to hear Island Pharmaceuticals’ David Foster on the trial results, the next phase’s details, and more.

 

This video was developed in collaboration with Island Pharmaceuticals, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.

Read MoreHealth

Featured Companies

You might be interested in